Electrolyte deficiency
0 original drugs 0
Novel Drugs
17
Reformulations
0
Active Trials
0
Drug Targets
Electrolyte deficiency has 0 FDA-approved novel treatments. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Novel Electrolyte deficiency Drugs by Company (New molecular entities)
No novel drugs found for this indication.
Reformulations (17 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER
VANTIVE US HLTHCARE
T5 2015
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER
VANTIVE US HLTHCARE
T5 2015
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER
VANTIVE US HLTHCARE
T3 2006
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER
VANTIVE US HLTHCARE
T3 2006
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER
VANTIVE US HLTHCARE
T3 2006
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER
Pfizer
T3 2000
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER
Fresenius Kabi
T5 1992
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
OTSUKA ICU MEDCL
T5 1985
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
OTSUKA ICU MEDCL
T5 1985
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
OTSUKA ICU MEDCL
T5 1985
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER
Fresenius Kabi
T5 1984
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER
Fresenius Kabi
T5 1984
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER
Fresenius Kabi
T5 1984
DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER
VANTIVE US HLTHCARE
T5 1978
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
VANTIVE US HLTHCARE
T5 1978
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
VANTIVE US HLTHCARE
T5 1978
RINGER'S IN PLASTIC CONTAINER
Baxter
T5 1971
Generic Drugs (2 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs